Volume : 2, Issue : 7, JUL 2016

PERCEIVED INSIGHT AND ATTITUDE TOWARDS ANTIPSYCHOTIC MEDICATION AMONG PERSONS WITH SCHIZOPHRENIA

G. Majhi, A.R Singh

Abstract

Background: Generally, among persons with schizophrenia, insight into the illness and attitudes towards medication, along with severity of illness, and social functioning, are known to be important in determining outcomes. Aim: The present study aims was to assess the level of insight of persons with schizophrenia and also their attitude towards adherence to antipsychotic medication. Methodology: Male in-patients with schizophrenia numbering 100 met the inclusion criteriawere selected for the study. Tools: Tools administered were socio-demographic datasheet, Brief Psychiatric Rating Scale (BPRS), Insight and treatment attitude questionnaire. (ITAQ), Drug Attitude Inventory (DAI) Result: Overall findings of this study suggest that, insight towards mental illness also poorly associated with adherence to treatment and drug compliance. Conclusion: Subjective acceptance of antipsychotic medications is higher for inpatients, but average number of subjects have shown negative attitude towards antipsychotic medicine because confounding factors over shadowed the real problem they encountered.

Article : Download PDF

Cite This Article

Article No : 29

Number of Downloads : 681

References

1. R C Kessler, P A Berglund, M L Bruce, J R Koch, E M Laska, P J Leaf, R W
Manderscheid, R A Rosenheck, E E Walters, P S Wang: The prevalence and correlatesof untreated serious mental illness, Health Serv Res. 2001 December; 36(6 Pt 1):987–1007.

2. Adams SG, Howe JT.(1993) Predicting medication compliance in a psychotic
population. J NervMent Dis; 181:558-560.
3. Amader XF, Flaum M, Anderason NC, et al(1994): Awareness of illness in
schizophrenia and schizoaffective and mood disorders; Archives of General Psychiatry
51: 826-836.
4. Awad GA, Voruganti LN, Heslegrave RJ, Hogan TP. (1996) Assessment of the patient's
subjective experience in acute neuroleptic treatment: implications for compliance and
outcome. IntClin Psychopharmacol.;11:55
5. AwadGA.(1993) Subjective response to neuroleptics in schizophrenia. Schizophr Bull;
19:609-618.
6. Coley RR and Buchanan RW.(1997) Evaluation of treatment – resistant schizophrenia.
Zchizopr Bull.; 23:663-674.
7. Coursey RD, Keller AB, FarrelEW . (1995) Individual psychotherapy and erosions
with serious mental illness: The client perspective. Schizophrenia Bulletin 21: 283-
301.
8. Csernansky J: (1999)Risperidone vs haloperidol for prevention of relapse in
schizophrenia and schizoaffective disorders: a long –term double –blind comparison.
Presented at the annual convention of the society of Bilogical Psychiatry held in
Washington, DC. May 13,
9. Fleischhacker WW, Meise U, Gunther V ,Kurz M. (1994)Compliance with
antipsychotic drug treatment : Influence of side effects. ActaPsychiatrScand ;89 (suppl.
382): 11-15.
10. Hogen TP, Awad AG, Eastwood R.(1983)A self-report scale predictive of drug
compliance in schizophrenics: reliability and discriminative validity. Psychological
medicine; 13:177-183.
11. Kampman O and LehtinenK.(1999) Compliance in Psychoses. Acta Psychitr Scand;
100: 167-175
12. Kane JM.(1985) Complience issues in outpatients treatment. J LcinPsychopharmacol.;
5 (3, Suppl) : 22s-27s.
13. Kissing W .(1994) Compliance, quality assurance and standard for relapse prevention
in schizophrenia. ActaPsychiatrscandsuppl.:382:16-24.
14. Lay P.(1992) The problem of patients' non compliance, in :communicating with
patients; improving communication satisfaction and compliance. London England
:Chapman & Hall;:53-71.
15. Lee S.(1993). The prevalence and nature of lithium noncompliance among Chinese
psychiatric patients in Hong Kong. J NervMent Dis.181:618–25.
16. LibermanRP,Kopelowich A Ventura JGutkind D.(2002)Operational criteria and
factors to recovery formschizophrenia.Int Rev Psychiatry;14:256-272.
17. Malla AK, Norman RM, Mclean TS et al (2004). Determinants of quality of life in firstepisode
psychosis. ActaPsychiatr Scand;109; 46-54.
18. McEnvoy JP, Apperson L.L Appelbaum , P.A. et al(1989) Insight in schizophrenia . Its
relationship to acute psychopathology. Journal of Nervous and Mental Disease, 177,
43-47.
19. McEnvoy JP, Howe AC, HogartyGE.(1984) Differences in the nature of relapse and
subsequent inpatient course between medication –compliant and noncompliant
schizophrenic patients. J NervMent Dis. 172: 412-416.
20. Procyshyn RM, ZerjavS.(1998)Drug utilization patterns and outcomes associated with
hospital treatment with respiridone or olanzapine. Clin Ther;20;1203-
1217.discussion1192-1203.
21. Rabinowitz J , Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M.
(2001)Rehospitalization rates of chronically ill schizophrenic patients discharge on a
regimen of respiridone , olanzapine, or conventional antipsychotics. Am J Psychiatry;
158: 266-269.
22. Tran PV, Hamilton SH, Kuntz AJ et al .(1997)Dcomparition of olanzapine vs.
Rispiridone in the treatment of schizophrenia and other psychotic disorders. J Clin
Psychopharmacol:17: 407-418.
23. Van puttanT.(1974) Why do schizophrenia patients refuse to take their drugs ? Arch
Gen Psuchiatry .: 31: 67-72.
24. Weinden PJ, Dixon L, Frances A, Appelbaum P, Haas G, Rapkin B. (1991) Neuroleptic
noncompliance in schizophrenia. In: Tamminga CA, Shutz SC, eds. Advances in
Neupsychiatry and Psychopharmachology. Vol I: Schizophrenia Research. New York,
NY: Raven Press; 285-296.
25. Naoaki Kuroda, Shiyou Sun, Chih-KuangLin,Nobuaki Morita, HirotakaKashiwase,
Fude Yang,and Yoji Nakatani (2008) Attitudes toward taking medication among
outpatients with schizophrenia: cross-national comparison between Tokyo and Beijing
.Environ Health Prev Med. Sep; 13(5): 288–295.